- Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
-
Banerjee R, Raja Ali RA, Wei SC, Adsul S
- KMID: 2508688
- Gut Liver.
- 2020 Nov;14(6):685-698.
- doi: 10.5009/gnl19209
The advent of biologics and biologic therapy has transformed the management of inflammatory bowel disease (IBD) with enhanced early and adequate responses to treatment, fewer hospitalizations, a reduced need for... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
-
Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S
- KMID: 2512103
- Intest Res.
- 2021 Jan;19(1):71-82.
- doi: 10.5217/ir.2019.09159
Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
-
Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S
- KMID: 2512104
- Intest Res.
- 2021 Jan;19(1):83-94.
- doi: 10.5217/ir.2019.09160
Background/Aims: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
